Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results.

e16088 Background: New emerging therapies for mCRPC, such as CBZ, have prompted the need to identify appropriate patients (pts) for each specific treatment. Updated data on the experience with CBZ in mCRPC pts in Spain with longer follow-up is presented. Methods: Medical records from docetaxel-resistant mCRPC pts receiving CBZ at 19 centres in Spain were reviewed retrospectively. Baseline characteristics, PSA response, overall survival (OS), radiographic progression-free survival (rPFS), and toxicity were collected. Results: Data from 99 consecutive pts (median age 70 years) were reviewed: ECOG 0-1 (77.2%), Gleason score of 7-10 (83.6%), visceral involvement (24.5%), pain (72.7%) and radiological progression (69.7%) at CBZ initiation. Median duration of response to first-line androgen deprivation therapy (ADT) was 20.8 months (mo). Most pts received ≤2 hormonal lines (77.8%) and only one docetaxel line (76.8%) before CBZ. Forty-three (43.4 %) pts had progressed on docetaxel, 31 (31.3%) <6 mo and 25 (25.3%...